Corinne Jenkins
Stock Analyst at Goldman Sachs
(2.31)
# 2,604
Out of 5,165 analysts
58
Total ratings
43.9%
Success rate
0.3%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Corinne Jenkins
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ROIV Roivant Sciences | Maintains: Buy | $24 → $33 | $28.28 | +16.69% | 7 | Dec 15, 2025 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $141 → $157 | $90.51 | +73.46% | 11 | Dec 12, 2025 | |
| IDYA IDEAYA Biosciences | Maintains: Neutral | $27 → $30 | $34.79 | -13.77% | 6 | Oct 21, 2025 | |
| GERN Geron | Reinstates: Sell | $1 | $1.65 | -39.39% | 4 | Jul 10, 2025 | |
| TGTX TG Therapeutics | Maintains: Neutral | $20 → $22 | $28.77 | -23.53% | 8 | Nov 5, 2024 | |
| FULC Fulcrum Therapeutics | Upgrades: Buy | $6 → $15 | $7.44 | +101.61% | 2 | May 14, 2024 | |
| ALT Altimmune | Reinstates: Neutral | $13 | $3.62 | +259.12% | 3 | Jan 24, 2024 | |
| HRMY Harmony Biosciences Holdings | Maintains: Sell | $25 → $28 | $27.86 | +0.50% | 7 | Jan 9, 2024 | |
| BTAI BioXcel Therapeutics | Maintains: Neutral | $192 → $64 | $1.54 | +4,055.84% | 6 | Aug 15, 2023 | |
| ACRS Aclaris Therapeutics | Maintains: Buy | $25 → $21 | $3.74 | +461.50% | 2 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 → $14 | $46.07 | -69.61% | 2 | Dec 20, 2022 |
Roivant Sciences
Dec 15, 2025
Maintains: Buy
Price Target: $24 → $33
Current: $28.28
Upside: +16.69%
Rhythm Pharmaceuticals
Dec 12, 2025
Maintains: Buy
Price Target: $141 → $157
Current: $90.51
Upside: +73.46%
IDEAYA Biosciences
Oct 21, 2025
Maintains: Neutral
Price Target: $27 → $30
Current: $34.79
Upside: -13.77%
Geron
Jul 10, 2025
Reinstates: Sell
Price Target: $1
Current: $1.65
Upside: -39.39%
TG Therapeutics
Nov 5, 2024
Maintains: Neutral
Price Target: $20 → $22
Current: $28.77
Upside: -23.53%
Fulcrum Therapeutics
May 14, 2024
Upgrades: Buy
Price Target: $6 → $15
Current: $7.44
Upside: +101.61%
Altimmune
Jan 24, 2024
Reinstates: Neutral
Price Target: $13
Current: $3.62
Upside: +259.12%
Harmony Biosciences Holdings
Jan 9, 2024
Maintains: Sell
Price Target: $25 → $28
Current: $27.86
Upside: +0.50%
BioXcel Therapeutics
Aug 15, 2023
Maintains: Neutral
Price Target: $192 → $64
Current: $1.54
Upside: +4,055.84%
Aclaris Therapeutics
Mar 7, 2023
Maintains: Buy
Price Target: $25 → $21
Current: $3.74
Upside: +461.50%
Dec 20, 2022
Maintains: Buy
Price Target: $9 → $14
Current: $46.07
Upside: -69.61%